|Articles|September 1, 2002
IPO positions Alcon for tomorrow
Author(s)Mark L. Dlugoss
Fort Worth, TX-Amid the fanfare of the New York Stock Exchange and company executives, Tim Sear of Alcon Laboratories Inc. and Peter Brabeck-Letmathe of Nestl? A stood atop the balcony overlooking the trading floor and rang the opening bell, marking the official start of the day on Wall Street.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
3
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
4
PRIMA retinal implant restores vision in patients with advanced GA
5










































